Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05748873 · ClinicalTrials.gov registry record · Phase 1
Promising ROd-cone DYstrophy Gene therapY
A Phase 1 study of Retinitis Pigmentosa, sponsored by SparingVision.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
- 6
- Study locations
NCT05748873: Recruiting Phase 1 study of Retinitis Pigmentosa, sponsored by SparingVision.
NCT05748873 is a Phase 1 study of Retinitis Pigmentosa that is actively recruiting participants, run by SparingVision. The registered enrollment target is 33 participants, below the 260-participant average among 37 other Retinitis Pigmentosa trials with a reported enrollment target (87% lower). The trial reports 6 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05748873, a Phase 1 study of Retinitis Pigmentosa, is actively recruiting participants, sponsored by SparingVision.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
- 6
- Study locations
Study Summary
This is a two-step, multicenter, Phase I/II study including an open-label dose-escalation phase (Step 1) and a three-arm, controlled, double-masked, randomized extension phase (Step 2), in subjects with advanced RCD due to a mutation in the RHO, PDE6A, or PDE6B gene.
Primary Outcome
Incidence and severity of systemic and ocular AEs and SAEs
Conditions Studied
Interventions
- DRUG SPVN06
Study Locations (6)
Florida
- Bascom Palmer Eye Institute/University of Miami - Miami
Massachusetts
- Mass Eye and Ear - Boston
Oregon
- Casey Eye Institute - Portland
Pennsylvania
- UPMC Eye Center - Pittsburgh
Texas
- Retina Foundation of the Southwest - Dallas
Other
- CHNO XV-XX Paris - CIC 1423 - Paris
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2023-04-12 |
| Est. Completion | 2030-09 |
| Phase | Phase 1 |
What NCT05748873 shows while recruiting
NCT05748873 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 260-participant average among 37 other Retinitis Pigmentosa trials with a reported enrollment target (87% lower).
The record links to 1 condition, with Retinitis Pigmentosa appearing as the primary indexed condition, and to 1 intervention - of which SPVN06 is the first listed.
NCT05748873 lists 6 locations in 6 states (Florida, Massachusetts, Oregon).
Frequently Asked Questions
What is clinical trial NCT05748873 about?
NCT05748873 is a clinical study titled "Promising ROd-cone DYstrophy Gene therapY". This is a two-step, multicenter, Phase I/II study including an open-label dose-escalation phase (Step 1) and a three-arm, controlled, double-masked, randomized extension phase (Step 2), in subjects with advanced RCD due to a mutation in the RHO, PDE6A, or PDE6B gene.
What is the current status of trial NCT05748873?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2023-04-12. Estimated completion is 2030-09.
What conditions does trial NCT05748873 study?
This clinical trial studies the following conditions: Retinitis Pigmentosa.
What interventions are being tested in trial NCT05748873?
The interventions under investigation include: SPVN06 (DRUG).
Who is sponsoring clinical trial NCT05748873?
This trial is sponsored by SparingVision, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05748873 being conducted?
This trial has 6 study locations across Florida, Massachusetts, Oregon, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Retinitis Pigmentosa
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05748873's enrollment target sits among peer trials
33 20th of 37 higher than 18 of 37 other Retinitis Pigmentosa trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Retinitis Pigmentosa trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Investigate the Safety of DSP-3077 After a Unilateral Eye Injection in Male and Female Participants 18 Years of Age or Older With Retinitis Pigmentosa
RECRUITING · Phase 1
-
BS01 in Patients With Retinitis Pigmentosa
RECRUITING · Phase 1
-
The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration
RECRUITING · Phase 1
-
Clinical Trial of Autologous Intravitreal Bone-marrow CD34+ Stem Cells for Retinopathy
ACTIVE NOT RECRUITING · Phase 1
-
Study to Evaluate Safety of RTx-015 Injection in Retinitis Pigmentosa or Choroideremia Patients (ENVISION)
ACTIVE NOT RECRUITING · Phase 1
-
CNS10-NPC for the Treatment of RP
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI